All patients
invasive ventilation non invasive oxygen
remdesivir in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results NIH NIAID ACTT-1, 2020 0.73 [0.52; 1.03]
0.73 [0.52 ; 1.03 ] NIH NIAID ACTT-1, 2020 1 0% 1,062 NA not evaluable deathsdetailed results CAP-China (Wang et al.), 2020 1.10 [0.49; 2.45]
NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84]
0.71 [0.37 ; 1.37 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 56% 1,298 moderate not evaluable deaths (time to event analysis only)detailed results NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84]
0.55 [0.36 ; 0.84 ] NIH NIAID ACTT-1, 2020 1 0% 1,062 NA not evaluable clinical deteriorationdetailed results CAP-China (Wang et al.), 2020 0.95 [0.55; 1.64]
0.95 [0.55 ; 1.64 ] CAP-China (Wang et al.), 2020 1 0% 237 NA not evaluable clinical improvementdetailed results CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49]
1.28 [1.12 ; 1.46 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,299 moderate not evaluable clinical improvement (14-day)detailed results CAP-China (Wang et al.), 2020 1.21 [0.64; 2.28]
1.21 [0.64 ; 2.28 ] CAP-China (Wang et al.), 2020 1 0% 236 NA not evaluable clinical improvement (28-day)detailed results CAP-China (Wang et al.), 2020 1.37 [0.79; 2.39]
NIH NIAID ACTT-1, 2020 1.35 [1.03; 1.76]
1.35 [1.07 ; 1.72 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,298 moderate not evaluable clinical improvement (7-day)detailed results CAP-China (Wang et al.), 2020 0.99 [0.18; 5.51]
0.99 [0.18 ; 5.51 ] CAP-China (Wang et al.), 2020 1 0% 236 NA not evaluable clinical improvement (time to event analysis only)detailed results CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49]
1.28 [1.12 ; 1.46 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,299 moderate not evaluable AE leading to drug discontinuationdetailed results CAP-China (Wang et al.), 2020 2.43 [0.79; 7.45]
2.43 [0.79 ; 7.45 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable serious adverse eventsdetailed results CAP-China (Wang et al.), 2020 0.64 [0.33; 1.23]
NIH NIAID ACTT-1, 2020 0.72 [0.54; 0.96]
0.71 [0.55 ; 0.92 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable deep vein thrombosisdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
NIH NIAID ACTT-1, 2020 0.64 [0.23; 1.81]
0.62 [0.23 ; 1.64 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable elevated liver enzymesdetailed results CAP-China (Wang et al.), 2020 0.36 [0.13; 1.01]
NIH NIAID ACTT-1, 2020 0.67 [0.38; 1.18]
0.58 [0.34 ; 0.97 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 6% 1,296 moderate not evaluable hyperbilirubinemiadetailed results CAP-China (Wang et al.), 2020 1.09 [0.42; 2.79]
NIH NIAID ACTT-1, 2020 0.84 [0.30; 2.34]
0.97 [0.48 ; 1.93 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 low not evaluable pulmonary embolismdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
NIH NIAID ACTT-1, 2020 0.96 [0.19; 4.80]
0.82 [0.20 ; 3.29 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable renal impairmentdetailed results CAP-China (Wang et al.), 2020 1.01 [0.03; 30.33]
NIH NIAID ACTT-1, 2020 1.02 [0.64; 1.61]
1.02 [0.64 ; 1.61 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-16 19:54 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 510
- roots T: 290